Mihai Cosmin-Teodor, Mihaila Ilarion, Pasare Maria Antoanela, Pintilie Robert Mihai, Ciorpac Mitica, Topala Ionut
Advanced Research and Development Center for Experimental Medicine (CEMEX), Grigore T. Popa University of Medicine and Pharmacy of Iasi, 700115 Iasi, Romania.
Integrated Centre of Environmental Science Studies in the North-Eastern Development Region (CERNESIM), Alexandru Ioan Cuza University of Iasi, 11 Carol I Blvd., 700506 Iasi, Romania.
Curr Issues Mol Biol. 2022 Apr 30;44(5):1995-2014. doi: 10.3390/cimb44050135.
The use of plasma-activated media (PAM), an alternative to direct delivery of cold atmospheric plasma to cancer cells, has recently gained interest in the plasma medicine field. Paclitaxel (PTX) is used as a chemotherapy of choice for various types of breast cancers, which is the leading cause of mortality in females due to cancer. In this study, we evaluated an alternative way to improve anti-cancerous efficiency of PTX by association with PAM, the ultimate achievement being a better outcome in killing tumoral cells at smaller doses of PTX. MCF-7 and MDA-MB-231 cell lines were used, and the outcome was measured by cell viability (MTT assay), the survival rate (clonogenic assay), apoptosis occurrence, and genotoxicity (COMET assay). Treatment consisted of the use of PAM in combination with under IC50 doses of PTX in short- and long-term models. The experimental data showed that PAM had the capacity to improve PTX's cytotoxicity, as viability of the breast cancer cells dropped, an effect maintained in long-term experiments. A higher frequency of apoptotic, dead cells, and DNA fragmentation was registered in cells treated with the combined treatment as compared with those treated only with PT. Overall, PAM had the capacity to amplify the anti-cancerous effect of PTX.
使用等离子体活化介质（PAM）作为将冷大气等离子体直接递送至癌细胞的替代方法，最近在等离子体医学领域引起了关注。紫杉醇（PTX）用作各种类型乳腺癌的首选化疗药物，乳腺癌是女性癌症死亡的主要原因。在本研究中，我们评估了一种通过与PAM联合来提高PTX抗癌效率的替代方法，最终目标是以更小剂量的PTX在杀死肿瘤细胞方面取得更好的效果。使用了MCF-7和MDA-MB-231细胞系，并通过细胞活力（MTT法）、存活率（克隆形成试验）、凋亡发生率和遗传毒性（彗星试验）来衡量结果。在短期和长期模型中，治疗包括使用PAM与低于IC50剂量的PTX联合。实验数据表明，PAM有能力提高PTX的细胞毒性，随着乳腺癌细胞活力下降，这种效应在长期实验中得以维持。与仅用PT治疗的细胞相比，联合治疗的细胞中凋亡、死亡细胞和DNA片段化的频率更高。总体而言，PAM有能力放大PTX的抗癌作用。
